Senores Pharmaceuticals Ltd. Stock Analysis SENORES.NS

Senores Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceutical and generic medicines. The company is headquartered in Ahmedabad, Gujarat and currently employs 194 full-time employees. The company went IPO on 2024-12-30. The firm manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The firm's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. The company supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.